Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 4Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Pulmonary Blastoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Pancreatic Neoplasms 1Pain, Intractable 1Neuroblastoma 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Melanoma, Cutaneous Malignant 1Melanoma 1Lymphoma 1Li-Fraumeni Syndrome 1Leukemia, Plasma Cell 1Leukemia 1Legius syndrome 1Hematologic Neoplasms 1Gliosarcoma 1

Interventions

sargramostim 1iberdomide 1dinutuximab 1Topotecan 1Magnetic Resonance Spectroscopy 1Cyclophosphamide 1Colony-Stimulating Factors 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × NIH × Ganglioneuroblastoma × Clear all
NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡